Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy.

Cabrera Figueroa S, Fernández de Gatta M, Hernández García L, Domínguez-Gil Hurlé A, Bustos Bernal C, Sepúlveda Correa R, García Sánchez MJ.

Ther Drug Monit. 2010 Oct;32(5):579-85. doi: 10.1097/FTD.0b013e3181f0634c.

PMID:
20720517
2.

Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, Fujimoto K, Sato I, Ueda M, Horiba M, Hamaguchi M, Yamamoto M, Takata N, Kimura A, Koike T, Gejyo F, Matsushita S, Shirasaka T, Kimura S, Oka S.

Clin Infect Dis. 2007 Nov 1;45(9):1230-7. Epub 2007 Sep 24.

PMID:
17918089
3.

Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.

Saitoh A, Fletcher CV, Brundage R, Alvero C, Fenton T, Hsia K, Spector SA.

J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):280-5.

PMID:
17356468
4.

Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.

Cabrera SE, Santos D, Valverde MP, Domínguez-Gil A, González F, Luna G, García MJ.

Antimicrob Agents Chemother. 2009 Jul;53(7):2791-8. doi: 10.1128/AAC.01537-08. Epub 2009 May 11.

5.

Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV.

Cabrera Figueroa S, Iglesias Gómez A, Sánchez Martín A, de la Paz Valverde Merino M, Domínguez-Gil Hurlé A, Cordero Sánchez M.

Clin Drug Investig. 2010;30(6):405-11. doi: 10.2165/11535320-000000000-00000.

PMID:
20441246
6.

Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.

Puthanakit T, Tanpaiboon P, Aurpibul L, Cressey TR, Sirisanthana V.

Antivir Ther. 2009;14(3):315-20.

PMID:
19474465
7.

Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.

Heil SG, van der Ende ME, Schenk PW, van der Heiden I, Lindemans J, Burger D, van Schaik RH.

Ther Drug Monit. 2012 Apr;34(2):153-9. doi: 10.1097/FTD.0b013e31824868f3.

PMID:
22354160
8.
9.

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.

Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Décosterd L, Telenti A; Swiss HIV Cohort Study.

Pharmacogenet Genomics. 2005 Jan;15(1):1-5.

PMID:
15864119
10.

Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children.

Viljoen M, Karlsson MO, Meyers TM, Gous H, Dandara C, Rheeders M.

Eur J Clin Pharmacol. 2012 Apr;68(4):339-47. doi: 10.1007/s00228-011-1148-7. Epub 2011 Nov 6.

PMID:
22057858
11.

Correlation of CYP2B6-516G > T Polymorphism with Plasma Efavirenz Concentration and Depression in HIV-Infected Adults in Northern Thailand.

Aurpibul L, Chotirosniramit N, Sugandhavesa P, Kosashunhanan N, Thetket S, Supindham T, Piyamongkol W, Supparatpinyo K.

Curr HIV Res. 2012 Dec;10(8):653-60.

PMID:
22950382
12.

Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphisms.

Mutwa PR, Fillekes Q, Malgaz M, Tuyishimire D, Kraats Rv, Boer KR, Burger DM, van Schaik RH, Muganga N, Geelen SP.

J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):400-4. doi: 10.1097/QAI.0b013e3182569f57.

PMID:
22481606
13.

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, Oka S.

Biochem Biophys Res Commun. 2004 Jul 9;319(4):1322-6.

PMID:
15194512
14.

Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese.

To KW, Liu ST, Cheung SW, Chan DP, Chan RC, Lee SS.

Ther Drug Monit. 2009 Aug;31(4):527-30. doi: 10.1097/FTD.0b013e3181ad74a4.

PMID:
19531981
15.

CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.

Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH.

Br J Clin Pharmacol. 2009 Apr;67(4):427-36. doi: 10.1111/j.1365-2125.2009.03368.x.

16.

CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.

Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Kumar P, Ramesh K, Anitha S, Narendran G, Menon P, Gomathi C, Swaminathan S.

Antimicrob Agents Chemother. 2009 Mar;53(3):863-8. doi: 10.1128/AAC.00899-08. Epub 2009 Jan 5.

17.

CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.

Chen J, Sun J, Ma Q, Yao Y, Wang Z, Zhang L, Li L, Sun F, Lu H.

Ther Drug Monit. 2010 Oct;32(5):573-8. doi: 10.1097/FTD.0b013e3181ea953c.

PMID:
20625352
18.

A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations.

ter Heine R, Scherpbier HJ, Crommentuyn KM, Bekker V, Beijnen JH, Kuijpers TW, Huitema AD.

Antivir Ther. 2008;13(6):779-87.

PMID:
18839779
19.

The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients.

Bienvenu E, Swart M, Dandara C, Ashton M.

Antiviral Res. 2014 Feb;102:44-53. doi: 10.1016/j.antiviral.2013.11.011. Epub 2013 Dec 5.

PMID:
24316028
20.

Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.

Meng X, Yin K, Wang J, Dong P, Liu L, Shen Y, Shen L, Ma Q, Lu H, Cai W.

PLoS One. 2015 Jun 24;10(6):e0130583. doi: 10.1371/journal.pone.0130583. eCollection 2015.

Supplemental Content

Support Center